TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Impact · against what's priced in

TScan Therapeutics is moving toward a pivotal trial for TSC-101 in Q2 2026 and has resolved manufacturing scalability risks. While the upcoming two-year relapse data presentation is a key value driver, the primary catalysts are the transition to a pivotal trial and the implementation of a commercial-ready process.

TCRX+0.40

No priced-in read yet